GSK plcLSE: GSK

GSK: Director/PDMR Shareholding

· Issued by GSK plc via RNS

Summary by 6ix AI

Dr Hal Barron, Non-Executive Director of GSK plc, and two senior executives acquired notional GSK American Depositary Shares (ADS, shares traded on the New York Stock Exchange) in their GSK Executive Supplemental Savings Plan accounts following the reinvestment of dividends. Dr Barron also acquired ADS in his GSK 401(k) plan account. All were dated November 13, 2026.

Key details

  • Dr Hal Barron acquired 2,259.160 notional ADS (units credited within the savings plan account) at $50.4500 in his GSK Executive Supplemental Savings Plan account, and 72 ADS at $50.4500 in his GSK 401(k) plan account.
  • James Ford, SVP and Group General Counsel, Legal and Compliance, acquired 53.408 notional ADS at $50.4500 in his GSK Executive Supplemental Savings Plan account.
  • Maya Martinez-Davis, President, US, acquired 81.902 notional ADS at $50.4500 in her GSK Executive Supplemental Savings Plan account.
  • The place of each transaction is given as the New York Stock Exchange.

6ix AI wrote this summary from the release below and checked it against the release.

GSK PLC
17 November 2026

GSK plc (the ‘Company’)

Transaction notification

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.4500

2,259.160

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-11-13

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADS within Mr Ford’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.4500

53.408

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-11-13

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Maya Martinez-Davis

b)

Position/status

President, US

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.4500

81.902

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-11-13

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS within Dr Barron’s GSK 401(k) plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.4500

72

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-11-13

f)

Place of the transaction

New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

GSK plc on 6ix

Story so far

Earlier from GSK

All GSK news releases